Navigation Links
Multiple myeloma patients experience high response rate with new 3-drug combination
Date:12/5/2009

NEW ORLEANSA new three-drug combination has shown in a phase 1/2 clinical trial that it is a "highly effective regimen" in the treatment of patients newly diagnosed with multiple myeloma, a cancer of white blood cells in bone marrow, say researchers from Dana-Farber Cancer Institute.

Partial responses or better were seen in all of the 66 patients treated with the drug combination in the multi-center study, with 74 percent having a "very good partial response rate" in the phase 2 population, reports Paul G. Richardson, MD, of Dana-Farber, who led the study. The rate of complete or "near complete" responses to the therapy was also encouraging at 54 percent.

Richardson will describe the results in an oral presentation at the American Society of Hematology's 51st annual meeting on Saturday, Dec. 5 (Abstract 1218, Ernest N. Morial Convention Center, Hall E, 5:30-7:30 pm CT).

The regimen, known as RVD, combined the drugs Revlimid (lenalidomide), Velcade (bortezomib) and dexamethasone, which previously were found to be highly effective in multiple myeloma patients who had relapsed or no longer responded to first-line therapies.

Fifteen of the 35 newly diagnosed patients in the open-label phase 2 portion of the study subsequently underwent autologous (using their own blood-forming stem cells) transplants, a standard treatment for multiple myeloma "and did very well," says Richardson.

For the entire group, after a median 19.3 months of follow up, the median time-to-progression (TTP) of the disease, progression-free survival (PFS), and overall survival (OS) had not yet been reached, according to the presentation. The estimated TTP and PFS at one year are 76 percent, and the estimated one-year overall survival is 100 percent, the results showed.

An estimated 20,580 new cases of multiple myeloma will be diagnosed in 2009, according to the American Cancer Society, and 10,580 patients will die from the disease.

<
'/>"/>
Contact: Teresa Herbert
teresa_herbert@dfci.harvard.edu
617-632-5653
Dana-Farber Cancer Institute
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Timing of Multiple-Ligament Knee Surgery May Not Matter
2. Childbirth May Slow Progression of Multiple Sclerosis
3. Multiple Health Conditions Discovered During Free Clinic for Uninsured People in New Orleans
4. Patient Advocate Foundation Announces Additional Support for Co-Pay Relief Program Serving Multiple Myeloma Patients
5. Dallas Bariatric Surgeon Offers Multiple Options for Patients Considering Weight Loss Surgery in a Rough Economy
6. Catheter-Delivered Valve May Help People With Heart Defects Avoid Multiple Surgeries
7. New IVF Guidelines Aim to Reduce Multiple Births
8. Gentle touch may aid multiple sclerosis patients
9. People with Multiple Sclerosis are Proactively Improving their Walking, Energy Level, Confidence and Quality of Life
10. Early Drug Treatment May Cut Multiple Sclerosis Risk
11. Nine International Research Teams Collaborate to Successfully Operate Multiple Biomedical Robots from Numerous Locations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2015)... Indiana Fiber Network, LLC (IFN), the ... Mutual Insurance Company has selected IFN as a fiber ... at Brotherhood Mutual Insurance Company states: “IFN’s broadband fiber ... Mutual needed. We were interested in building ... us to ensure we achieved both. ” ...
(Date:4/26/2015)... India Network Foundation, a non-profit organization ... services to the Asian Indian community in the United ... more than two decades. The India News Network Digest ... around the world with the latest news items from ... Immigration Law Forum Digest, edited and contributed by Sheela ...
(Date:4/26/2015)... 2015 The grand celebration got off to ... Dettor, CCAR’s Managing Director. Deb then introduced Sandy Valentine, the ... in attendance because of his Walk for Recovery ... able to express his gratitude to the volunteers via video. ... dedication to carrying out CCAR’s mission. Volunteer Manager Conrad ...
(Date:4/25/2015)... Francisco, California (PRWEB) April 26, 2015 ... his search for original 1965 Rolling Stones Greensboro Coliseum concert ... and was part of the Stone's Second American Tour. ... by Globe Poster Company out of Baltimore, Maryland. This ... in the northeast and southern cites. Globe uses garish ...
(Date:4/25/2015)... York, New York (PRWEB) April 25, 2015 ... ) established for vaginal mesh lawsuits filed against ... the U.S. District Court, Southern District of West ... 9th, a Scheduling Conference was convened that day, ... Plaintiffs’ Master Long Form Complaint. The Order directed ...
Breaking Medicine News(10 mins):Health News:Brotherhood Mutual Insurance Company Selects Indiana Fiber Network, LLC for Fiber Transport Service 2Health News:Brotherhood Mutual Insurance Company Selects Indiana Fiber Network, LLC for Fiber Transport Service 3Health News:North American Telugu Society Bestows Community Service Award to India Network Foundation for Its Generosity and Sponsor of Visitor Health Insurance to Indian Visitors 2Health News:North American Telugu Society Bestows Community Service Award to India Network Foundation for Its Generosity and Sponsor of Visitor Health Insurance to Indian Visitors 3Health News:The Connecticut Community for Addiction Recovery (CCAR) honors its volunteers during National Volunteer Recognition Week. 2Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 2Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 3Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 4
... taken on time , , WEDNESDAY, May 7 (HealthDay News) -- ... miss doses when reminded by an electronic pillbox that both ... of pills to take and how to take them, new ... National Institute on Aging, was presented recently at the American ...
... SPOKANE, Wash., May 7 MIPSolutions, Inc. (OTC,Bulletin ... the,University of Utah has revealed a significant development ... that Molecularly Imprinted,Ionomer (MII) beads imprinted to retain ... This translates into decreased development,time, a large amount ...
... in Spanish and Chinese . ... translational research grant program will fund a pilot ... appropriate and improved diabetes care in rural communities ... Diabetes Self-Management Program (DSME), will help Filipinos with ...
... DaVita Inc. (NYSE:,DVA) announced that its Board ... current stock repurchase program. The increase, together ... $250,000,000 of,the Company,s common stock. The stock ... http://www.newscom.com/cgi-bin/prnh/20020729/DAVITALOGO ), Rich Whitney, CFO, ...
... May 7 Vaccinogen Inc. said Dutch health,authorities licensed ... clearing the path to more than $100 million of,potential ... facility based in Emmen, The,Netherlands also paves the way ... the final step before the vaccine can be sold ...
... Despite a weakened economy, a,challenging airline industry, and ... summer vacation plans, travel industry experts,observe; but they ... ), Jim Grace, President and CEO of ... "At InsureMyTrip.com, we are,seeing noticeable changes in the ...
Cached Medicine News:Health News:Electronic Pillbox Helps Seniors Stick to Drug Regimens 2Health News:Electronic Pillbox Helps Seniors Stick to Drug Regimens 3Health News:MIPSolutions, Inc. Reduces Expense and Development Time Associated With Precious Metal Extraction 2Health News:International Diabetes Federation gives grant to Philippine diabetes education program 2Health News:Dutch Authorize Manufacture of Vaccinogen's New Cancer Vaccine; License Clears Path to European Production, Final FDA Trial 2Health News:InsureMyTrip.Com's Travel Insurance Tips for Protecting Your Summer Vacation 2Health News:InsureMyTrip.Com's Travel Insurance Tips for Protecting Your Summer Vacation 3
(Date:4/24/2015)... -- Hospira, Inc. (NYSE: HSP ), ... spoke about the importance of extrapolation in bringing biosimilars ... annual European Biosimilars Group conference in London ... publication of a pivotal white paper titled, "Why ... biosimilars." Speaking at the EGA conference, ...
(Date:4/23/2015)... , April 24, 2015  AbbVie (NYSE: ABBV ... Administration (FDA) has accepted its New Drug Application (NDA) ... two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), ... of adults with chronic genotype 4 (GT4) hepatitis C ... first all-oral, interferon-free therapy being evaluated by the FDA ...
(Date:4/23/2015)... 23, 2015 Once again, BeaconMedaes is meeting ... to patient safety. BeaconMedaes, priority is to ... disease. The next generation Zone Valve Box ... are now mounted in the assembly, allowing for ease ... ceiling tiles potentially releasing dust spores and other bacteria ...
Breaking Medicine Technology:Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 2Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 3Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 4Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 5Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 6Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 7U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7BeaconMedaes launches new Zone Valve Box Assembly 2
... The BIOM 3 (Binocular Indirect Ophthalmo-Microscope) incorporates ... microscope and enables a view of up to ... the BIOM 3 the eye may be rotated ... easily viewed. Even surgery through small pupils ...
... The Philips HeartStart Home Defibrillatorthe latest ... than 175,000 devices deployed, Philips is ... defibrillators on airplanes, and in airports, ... HeartStart Home Defibrillator is the first ...
... custom bars have a large body ... contacts (spaced 3 centimeters center-to-center) to ... repeated cleaning. Polarity indicators are molded ... handle fits our bar electrode styles. ...
... custom bars have a large body ... contacts (spaced 3 centimeters center-to-center) to ... repeated cleaning. Polarity indicators are molded ... handle fits our bar electrode styles. ...
Medicine Products: